"10.1371_journal.pone.0095404","plos one","2014-05-05T00:00:00Z","Georges Habineza Ndikuyeze; Anita Gaurnier-Hausser; Reema Patel; Albert S Baldwin; Michael J May; Patrick Flood; Erika Krick; Kathleen J Propert; Nicola J Mason","Division of Hematology/Oncology, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America; Office of Professional Studies in the Health Sciences, Drexel University College of Medicine, Philadelphia, Pennsylvania, United States of America; Antech Diagnostics, New Hyde Park, New York, United States of America; TheraLogics, Inc., Chapel Hill, North Carolina, United States of America; Lineberger Comprehensive Cancer Center and Department of Biology, University of North Carolina, Chapel Hill, North Carolina, United States of America; Department of Animal Biology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America; 7-020G Katz Centre for Pharmacy and Health Research, The University of Alberta, Edmonton, Alberta, Canada; Department of Clinical Studies, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America; Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States of America; Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America","Conceived and designed the experiments: AGH ASB MJM KJP NJM. Performed the experiments: GHN AGH RP EK NJM. Analyzed the data: GHN AGH MJM KJP NJM. Contributed reagents/materials/analysis tools: ASB MJM PF. Wrote the paper: GHN AGH NJM.","Dr. May is a named inventor on US patent number 8,242,240 (Anti-inflammatory compounds and uses thereof) that is owned by Yale University for the NBD peptide that is described in this manuscript. Dr. Baldwin is the founder of TheraLogics and therefore has commercial interests. Dr. Patel is employed by Antech Diagnostics. There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLoS ONE policies on sharing data and materials.","2014","05","Georges Habineza Ndikuyeze","GHN",9,TRUE,5,5,5,3,TRUE,TRUE,FALSE,0,NA,FALSE
